Skip to content
Sign in
AcceleratorBacked 1 network startup

StartUp Health

New York health-innovation company (since 2011) backing 500+ health founders in Moonshot communities: diagnostics, treatments, type 1 diabetes, Alzheimer's.

New York, United States startuphealth.com
Ticket
—Not published
Assets under management
—
Founded
2011
Stages
Pre-seedto Seed
Network startups backed
1
Co-investors
1most often with Dreamward Ventures

How they invest

Healthcare and academic founders working on 'Health Moonshots' (diagnostics, treatments, type 1 diabetes, Alzheimer's), supported through long-term communities and small investments. Mission alignment with a moonshot matters as much as stage.

Stage and ticket

Pre-seed and Seed; observed $75K pre-seed (Wink Biotherapeutics).

Geography

Global; 500+ startups from 30 countries.

What makes them say yes

  • Clear alignment with a Health Moonshot
  • Healthcare or academic founder credibility
  • Measurable health-outcome potential

Red flags

  • No direct health outcome
  • Founders unwilling to engage in a long-term community

Sectors

  • HealthTech

Stages

  • Pre-seed
  • Seed

Geographies

  • Global

How to approach

Wink Biotherapeutics (accelerator 2023, pre-seed 2025, co-backed by Dreamward) is the warm path. Apply to the Moonshot community that matches the product.

Partners

  • Steven KreinCo-founder
  • Unity StoakesCo-founder

Portfolio

1 network startup · no other company

One network company (Wink, type 1 diabetes therapeutics), consistent with the T1D moonshot.

Gaps in the portfolio

  • Low-cost diagnostics
  • Women's health
  • Primary-care AI

Network startups

  • Wink BiotherapeuticsSWC 2026 Finalist

    Preclinical biotech licensing University of Miami RNA aptamers to regenerate beta cells in type 1 diabetes and target solid tumours.

    United States · Biotech & life sciences

    • pre-seed · $75K · 19 May 2025Source
    • accelerator · 6 Jul 2023Source

Network startups that fit

5 analysed

Smartphone eyelid-photo AI that screens for anemia in seconds without a blood draw, aimed at low-resource care.

Blood-free anemia screening from a smartphone photo: a low-cost diagnostic with global reach, fitting the diagnostics moonshot.

55%confidence

Evidence from the records

  • “AI anemia detection”
  • “assesses risk in a few seconds, without a blood test”
Intro path
Wink Biotherapeutics founders (StartUp Health portfolio).
First step
Apply to the diagnostics Moonshot community.

Melbourne start-up developing an at-home urine test with machine learning to screen for endometriosis.

At-home urine test for endometriosis: women's-health diagnostics at R&D stage.

40%confidence

Evidence from the records

  • “Women's health diagnostics (endometriosis)”
  • “endometriosis screening from a simple urine sample”
First step
Apply once clinical validation data exist.

Tufts spin-off with an IRB-approved ingestible capsule that samples small-intestine microbiome and contents non-invasively.

Ingestible small-intestine sampling capsule with IRB approval: a novel diagnostic tool from Tufts.

40%confidence

Evidence from the records

  • “Ingestible small intestine sampling capsule”
  • “NSR/IRB approved for human use”
First step
Apply to the diagnostics community.

Mauritian AI-native healthcare operating system — Eva assistant plus sourced clinical intelligence — sold pay-per-consultation and white-labelled to distributors.

AI primary-care OS with insurer contracts in Mauritius: health-access technology from a physician-led team.

35%confidence

Evidence from the records

  • “Primary care operating system (AI, RAG, EVA agent)”
  • “Contracts signed with the two largest insurers in Mauritius”
First step
Apply with access-to-care outcome metrics.

Maternal-health device start-up using LiDAR to measure cervical dilation in labour and build a cervical data infrastructure for AI.

Cervical data device in clinical evaluation for childbirth: maternal-health diagnostics, early.

30%confidence

Evidence from the records

  • “Maternal health / obstetrics”
  • “CerviLite is a patented experimental device in clinical evaluation”
Intro path
Gust Accelerator and Octane LaunchPad (Lidavex investors).
First step
Apply after first clinical readout.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Co-investors

Most often with Dreamward Ventures

Sources

  1. 1startuphealth.com/startup-health-blog/wink-therapeutics-is-using-rna-tech-to-
  2. 2startuphealth.com/about

Profile compiled from public sources. Unknown fields are left empty rather than estimated.